Zhu Ranran, Jiang Juean, Wang Ting, Xu Ting, Wu Min, Liu Cuiping, Zhang Xueguang
Medical Biotechnology Institute of Soochow University, Suzhou, China.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013 Aug;29(8):862-5.
To investigate the expressions of costimulatory molecules OX40 and OX40L on peripheral blood mononuclear cells (PBMC) and their relationship with clinical characteristics of patients with primary Sjogren's syndrome (pSS).
Peripheral blood samples were collected from 51 pSS patients and 36 healthy subjects (HC). The expressions of OX40 and OX40L on PBMC were detected by immunofluorescence and flow cytometry. In addition, we observed the changes in the levels of OX40 and OX40L after treatment in 11 patients with primary pSS and searched for the relationship between their expression levels and patients' clinical manifestations.
The expression of OX40 on CD4(+);T cells in pSS patients was significantly higher than that in the HC group (8.65%±3.51% vs 5.68%±1.68%, P<0.01). However, there was no significant difference in OX40 expression on CD8(+);T cells between patient group and HC group. In comparison with HC group, the expression of OX40L on CD14(+); monocytes (6.76%±3.60% vs 3.15%±1.89%, P<0.01) and CD19(+);B cells (4.69%±2.40% vs 2.76%±1.33%, P<0.01) significantly increased in pSS patients. Moreover, OX40 expression on CD4(+);T cells and OX40L expression on monocytes and B cells rose significantly in active pSS patients compared with those in inactive patients. The expression levels of OX40 and OX40L were higher in pSS patients with multiple system damage than in patients with simple exocrine gland injury. In addition, immunosuppressive therapy significantly reduced the expressions of OX40 and OX40L.
The expressions of OX40 and OX40L on peripheral lymphocytes was upregulated in pSS patients. The high levels of OX40 and OX40L expression were significantly correlated with clinical outcome and therapeutic response, suggesting that OX40/OX40L pathway may play a critical role in pSS pathogenesis.
探讨共刺激分子OX40和OX40L在原发性干燥综合征（pSS）患者外周血单个核细胞（PBMC）上的表达及其与患者临床特征的关系。
收集51例pSS患者和36例健康对照者（HC）的外周血样本。采用免疫荧光和流式细胞术检测PBMC上OX40和OX40L的表达。此外，观察11例原发性pSS患者治疗后OX40和OX40L水平的变化，并寻找其表达水平与患者临床表现之间的关系。
pSS患者CD4(+)T细胞上OX40的表达显著高于HC组（8.65%±3.51% 对5.68%±1.68%，P<0.01）。然而，患者组与HC组CD8(+)T细胞上OX40的表达无显著差异。与HC组相比，pSS患者CD14(+)单核细胞（6.76%±3.60% 对3.15%±1.89%，P<0.01）和CD19(+)B细胞上OX40L的表达显著增加（4.69%±2.40% 对2.76%±1.33%，P<0.01）。此外，与非活动期患者相比，活动期pSS患者CD4(+)T细胞上OX40的表达以及单核细胞和B细胞上OX40L的表达显著升高。多系统损害的pSS患者OX40和OX40L的表达水平高于单纯外分泌腺损伤患者。此外，免疫抑制治疗显著降低了OX40和OX40L的表达。
pSS患者外周淋巴细胞上OX40和OX40L的表达上调。OX40和OX40L的高表达水平与临床结局和治疗反应显著相关，提示OX40/OX40L通路可能在pSS发病机制中起关键作用。
